Qube Research & Technologies LTD Exelixis, Inc. Transaction History

Qube Research & Technologies LTD

$65.7 Billion
Q3 2024

A detailed history of Qube Research & Technologies LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 1,987,580 shares of EXEL stock, worth $70.1 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,987,580

Previous 480,576 313.58%

Holding current value

$70.1 Million

Previous $10.8 Million 377.65%

% of portfolio

0.08%

Previous 0.02%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $33.1 Million - $41.6 Million	1,507,004 Added 313.58%	1,987,580 $51.6 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $9.45 Million - $11 Million	464,497 Added 2888.84%	480,576 $10.8 Million
Q4 2023 Feb 13, 2024	SELL	$19.25 - $24.13 $1.91 Million - $2.39 Million	-99,217 Reduced 86.05%	16,079 $385,000
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $1.82 Million - $2.17 Million	95,460 Added 481.25%	115,296 $2.52 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $360,420 - $406,241	19,836 New	19,836 $379,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $5.42 Million - $6.3 Million	362,209 Added 27.68%	1,670,991 $26.8 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $16.4 Million - $23.4 Million	1,048,698 Added 403.22%	1,308,782 $20.5 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $4.54 Million - $6.02 Million	260,084 New	260,084 $5.42 Million
Q1 2022 May 09, 2022	SELL	$17.03 - $22.67 $452,333 - $602,137	-26,561 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$15.84 - $21.88 $420,726 - $581,154	26,561 New	26,561 $486,000
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $763,341 - $1.09 Million	-42,526 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $873,058 - $1.07 Million	42,526 New	42,526 $961,000
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $1.32 Million - $1.78 Million	-71,642 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $3.06 Million - $3.98 Million	-147,807 Reduced 67.35%	71,642 $1.75 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $3.37 Million - $5.61 Million	204,646 Added 1382.46%	219,449 $5.21 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $214,051 - $322,705	14,803 New	14,803 $255,000
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $188,102 - $234,538	-12,416 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $42,714 - $54,722	-2,416 Reduced 16.29%	12,416 $220,000
Q2 2019 Aug 02, 2019	BUY	$18.93 - $24.75 $280,769 - $367,092	14,832 New	14,832 $317,000
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $142,847 - $228,137	-10,465 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $166,079 - $234,415	10,465 New	10,465 $185,000

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Exelixis, Inc. Transaction History